Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.06.002
Abstract: Ibrutinib is a new Bruton’s tyrosine kinase inhibitor associated with improvements in the outcomes of various B-cell hematologic malignancies and is now standard lifelong therapy in those without intolerance or disease progression [(1)][1]. However, there is a… read more here.
Keywords: initiation lymphoid; following ibrutinib; ventricular arrhythmias; ibrutinib initiation ... See more keywords